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Since the presentation of trials such as the Intergroup
N9741 study (National Cancer Institute of Canada
CO.15) and the MOSAIC (Multicenter International
Study of Oxaliplatin/5-FU–LV in the Adjuvant Treat-
ment of Colon Cancer) trial at the 2003 American
Society of Clinical Oncology meeting, oncologists
have broadly accepted that oxaliplatin is part of the
standard management of colorectal cancer, both in
the metastatic and adjuvant settings 1–4.
The Gastrointestinal Cancer Disease Site Group
within Cancer Care Ontario’s Program in Evidence-
Based Care (PEBC) immediately began the thorough
process of systematic review, development of evi-
dence-based recommendations, review by the Report
Approval Panel (a methodologic oversight group),
practitioner feedback, and eventual finalization and
publication of guidelines. For oxaliplatin in colorectal
cancer, that process was required for three settings:
• Metastatic colorectal cancer
• Resected colon cancer
• Resected rectal cancer
The guideline for the metastatic colorectal can-
cer setting was published in Current Oncology in
2006 5. The guideline for stages II and III colon can-
cer was updated to incorporate the most recent data
for oxaliplatin (Cancer Care Ontario, Program in
Evidence-Based Care. Evidence-based series 2-29:
Adjuvant systemic chemotherapy for stage II and III
colon cancer following complete resection. In devel-
opment). Final approval and publication of the
stages II and III colon and rectal cancer guidelines are
pending (Cancer Care Ontario, Program in Evidence-
Based Care. Evidence-based series 2-3, Ver. 2.2007.
Postoperative adjuvant radiotherapy and/or chemo-
therapy for resected stage II or III rectal cancer. In
development).
Once a guideline is made available by the PEBC, it
undergoes a joint review process in Ontario that evalu-
ates all cancer-related drugs for consideration under
the New Drug Funding Program or the Ontario Drug
Benefit program, or both. The Committee to Evalu-
ate Drugs (CED), an expert advisory committee to the
Ministry of Health and Long-Term Care, conducts
the joint review and makes a recommendation regard-
ing the funding of the drug in the province of
Ontario 6.
Given the intrinsic delays in the rigorous PEBC
guideline development cycle, the CED has always ac-
cepted late drafts of the recommendations to assist in
making timely decisions for emerging therapies. The
guidelines on colorectal cancer were therefore made
available to the CED in 2006.
Complicating the story for oxaliplatin was the
absence of a Health Canada Notice of Compliance
(NOC). In the context of the incomplete intellectual
property protection pertaining in Canada before Oc-
tober 2006, Sanofi-Aventis could not submit its con-
fidential data 7 from an extensive research and
development program without running the risk of
seeing its oxaliplatin product Eloxatin immediately
become genericized. When that situation changed,
and data protection provisions were read into law,
Sanofi-Aventis could then apply for 8 years of patent
protection under the new legislation.
And so, while the rest of the world’s regulators
approved oxaliplatin (the U.S. Food and Drug Admin-
istration’s approval for metastatic disease came in
2002, and for stage III colon cancer in 2004 8), Health
Canada could make oxaliplatin available only through
a special access program. Canadians were left with a
patchwork of provincial approaches to the coverage
of oxaliplatin. British Columbia provided the drug;
Quebec gave approval only on a hospital-by-hospi-
tal basis. Ontario took the rigid position that, as long
as the drug lacked a NOC, it could not be funded. On-
tario patients were at the mercy of the self-pay, albeit
generously Sanofi–Aventis-sponsored, Special Ac-
cess Program—a means-tested co-pay model.
On June 15, 2007, oxaliplatin received a NOC for
metastatic colorectal cancer, and the CED quickly re-
viewed the drug. The funding conditions announced
(Table I) in Ontario represent the most widespread
inclusive coverage for oxaliplatin of any province.
Although approval was long in coming, Ontario
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TABLE I Oxaliplatin approval in colorectal cancer
Clinical setting U.S. Food and Drug Administration Health Canada Notice of Compliance CCO PEBC Ontario
recommendations CED decision
Colorectal cancer
1st-Line metastatic “Use in combination with infusional 5-fluorouracil (5-FU) “Use in combination with 5-fluorouracil (5-FU) FOLFOX4, mFOLFOX6, Funded
and leucovorin (LV) for the initial treatment of advanced and leucovorin (LV) as treatment of patients or XELOX (FOLFOX regimens
colorectal cancer.” with metastatic colorectal cancer.” June 2005 at 85 mg/m2)
January 2004 June 15, 2007
2nd-Line metastatic Accelerated approval: “For use in combination with FOLFOX4, mFOLFOX6, Funded
(for example, infusional 5-FU/LV for the treatment of patients with or XELOX (FOLFOX regimens
post-FOLFIRI) metastatic carcinoma of the colon or rectum whose disease June 2005 at 85 mg/m2)
has recurred or progressed during or within six months of
completion of first-line therapy with the combination of
bolus 5-FU/LV and irinotecan”
August 9, 2002
Colon cancer
Stage III “Use in combination with infusional 5-fluorouracil/ No indication at present Recommendation Funded
leucovorin (5-FU/LV) for adjuvant treatment of stage III colon pending (FOLFOX or
cancer patients who have undergone complete resection of FLOX regimens
the primary tumor” at 85 mg/m2)
November 2004
Stage II No indication at present No indication at present Recommendation Funded
pending (FOLFOX or
FLOX regimens
at 85 mg/m2)
Rectal cancer
Stage II/III No indication at present No indication at present Recommendation Funded
pending (FOLFOX or
FLOX regimens
at 85 mg/m2)
CCO PEBC = Cancer Care Ontario, Program in Evidence-based Care; CED = Committee to Evaluate Drugs; FOLFOX = 5-fluorouracil/leucovorin/oxaliplatin; XELOX = capecitabine/oxaliplatin;
FOLFIRI = 5-fluorouracil/leucovorin/irinotecan; FLOX = bolus 5-fluorouracil/leucovorin/oxaliplatin.JONKER et al.
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patients and their oncologists now have one less
stressful issue to discuss during that first consulta-
tion: the financial issues surrounding oxaliplatin as
standard care.
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